OOIR: Observatory of International Research

Papers

(The H4-Index of Lancet Rheumatology is 41. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Real-world evidence for prehospital COVID-19 treatment in systemic autoimmune rheumatic disease	1542
Research in Brief	1315
Brachial plexopathy: an unusual manifestation of Takayasu arteritis	517
Can contextual factors improve clarity of the results from clinical trials of low back pain?	326
A disseminated gonococcal infection with spinal locations	229
Biological disease-modification in axial spondyloarthritis: insights from MRI	195
Thrombotic microangiopathy as a presentation of anti-synthetase syndrome	107
Molecular signature-based decision making in the era of targeted therapies for systemic lupus erythematosus	96
Women in rheumatology in Africa	93
Dual JAK and ROCK inhibition with CPL'116 in patients with rheumatoid arthritis with inadequate response to methotrexate: a randomised, double-blind, placebo-controlled, phase 2 trial	92
Reigniting the burnt-out health-care workforce	91
Three-dimensional, in-vitro approaches for modelling soft-tissue joint diseases	88
Post-COVID condition in patients with inflammatory rheumatic diseases: a prospective cohort study in the Netherlands	87
CAR T-cell therapy in autoimmune diseases: where are we and where are we going?	82
Associations of improvement in laboratory tests with clinical outcomes in patients with active systemic lupus erythematosus: a multinational longitudinal cohort study	74
1-year results of treatment with rituximab in polymyalgia rheumatica: an extension study of a randomised double-blind placebo-controlled trial	73
Patient involvement in digital rheumatology: lessons from practice	72
Pathways driving tendinopathy and enthesitis: siblings or distant cousins in musculoskeletal medicine?	69
Anti-tumour necrosis factor therapy for early-stage Dupuytren's disease (RIDD): a phase 2b, randomised, double-blind, placebo-controlled trial	67
Research in Brief	65
Outdoor temperatures and Raynaud's phenomenon in patients with systemic sclerosis	61
Assessing glucocorticoid toxicity: are the measures sensitive enough?	60
Correction to Lancet Rheumatol 2026; 8: e5–6	57
First-line biological versus conventional synthetic disease-modifying antirheumatic drug therapy in adult-onset Still's disease: a multicentre, retrospective, propensity weighted cohort study	56
Sex-related differences in patient characteristics, and efficacy and safety of advanced therapies in randomised clinical trials in psoriatic arthritis: a systematic literature review and meta-analysis	53

Biosimilars and the era of interchangeability	53
Preload deficiency as a treatable cause of fatigue and exercise intolerance in SLE	52
Early-stage Dupuytren's disease treatment; a promising next step?	51
Interleukin-5 inhibition in eosinophilic granulomatosis with polyangiitis: time for another approach?	47
Proof-of-concept studies in axial spondyloarthritis: there are no shortcuts	46
Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study	45
Artificial intelligence and high-dimensional technologies in the theragnosis of systemic lupus erythematosus	45
The association of outdoor temperature and self-reported Raynaud's phenomenon severity among people with systemic sclerosis: a Scleroderma Patient-centered Intervention Network Cohort study	44
Reclassifying ANCA-associated vasculitis: a focus on kidney disease	44
Addition of aerobic physical activity to resistance exercise for hip osteoarthritis (PHOENIX): a randomised comparative effectiveness trial	43
Baricitinib and ruxolitinib use through the UK HLH Network	43
Pain in clinical trials for knee osteoarthritis: estimation of regression to the mean	43
Additional SARS-CoV-2 vaccine doses: a little is better than none	43
Sex as a predictor of clinical phenotype and determinant of immune response in IgG4-related disease: a retrospective study of patients fulfilling the American College of Rheumatology–European League A	43
Environmental and societal factors associated with COVID-19-related death in people with rheumatic disease: an observational study	43
ANCA-associated large and small vessel vasculitis with aorto-pulmonary-renal syndrome	41